Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 5/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24730209 | 1.00 | BRAF (0.39) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL20050848 | 0.91 | KMT2A (0.35) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL20050579 | 0.91 | KMT2A (0.35) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL20051454 | 0.91 | KMT2A (0.35) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL20050288 | 0.88 | BRAF (0.38) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL29241531 | 0.88 | BRAF (0.38) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL29534315 | 0.88 | MEN1 (0.36) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL20051694 | 0.88 | MEN1 (0.36) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL29948441 | 0.88 | BRAF (0.40) | BRAFMEN1KMT2ALMNAMAPT | |
| SCHEMBL24730158 | 0.88 | BRAF (0.40) | BRAFMEN1KMT2ALMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343681-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2024-10-17 | — | — | US | disclosed |
| EP-4313939-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | Corteva Agriscience LLC (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204080-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | CORTEVA AGRISCIENCE LLC (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343681-A1 | MOLECULES HAVING PESTICIDAL UTILITY AND INTERMEDIATES AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | BRAF 3256/4885MEN1 1415/4885KMT2A 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.